)
Dalip Sethi
Commercial Lead for Cell Therapy Technologies (North America),
Terumo BCT
As an innovative and transformational leader, Dalip Sethi, currently serves as the commercial lead for Terumo BCT’s Cell Therapy Technologies portfolio in North America. He holds a doctorate and conducted post-doctoral studies at Thomas Jefferson University, School of Medicine. Throughout his career in the industry, Dalip has been engaged in developing technologies & methods for use in cell therapy applications. Dalip has authored multiple scientific publications and is a co-inventor on several patents & patent applications. He recently co-authored publications on modular automated systems for CD3+ T-cell manufacturing and monoculture of cord-blood derived CD34+ using an automated, membrane-based dynamic perfusion system. The articles highlighted the benefits of modular automation in cell therapy manufacturing. Dalip is also an ISCT member and participates in committees focused on cold chain, particulates, and process analytical technologies.